CUV 0.00% $14.30 clinuvel pharmaceuticals limited

I like:- Increase of 121% on the March quarter 2019.- Financial...

  1. 970 Posts.
    lightbulb Created with Sketch. 529
    I like:

    - Increase of 121% on the March quarter 2019.
    - Financial year-end Cash Receipts to June 2019 of $32,221,000 wereup 36% compared to the prior financial year (to June 2018).
    - This indicates that more EPP patients in Europe arereceiving treatment with SCENESSE® and we look forward to the time the same treatment access can be provided toAmerican EPP patients who have no current alternatives.”
    - Net Cash from Operations was positive by $8,618,000 in the June quarter 2019. Net Cash from Operations for thetwelve months to 30 June 2019 was a positive $18,382,000 compared to a positive $11,693,000 in the same twelvemonth period to 30 June 2018.
    - Increasing cash balance - Cash Balance as at 30 June2019 increased to $54,269,000, compared to $44,975,000 as at 31 March 2019 and $36,198,000 as at 30 June 2018.

    Very positive outlook and building blocks foundation.

    Well done!
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.